Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.arvato services healthcare Introduces Bridge To Europe
arvato services healthcare said that this new approach is based on its expertise and network and is expected to enable US and other non-European companies to furnish medical
arvato services healthcare said that this new approach is based on its expertise and network and is expected to enable US and other non-European companies to furnish medical
NiKem Research said that Toxicokinetic (TK) studies are allowed to correlate plasma and/or organ exposure of NCEs (and metabolites) to tolerated doses in toxicology studies. NiKem Research has
As per the expanded agreement, in addition to antibody OMP-21M18, SynCo will fill batches of OncoMed’s investigational products, two additional antibodies in the OncoMed pipeline for use in
Reportedly, FDA was notified by the New York City Department of Health and Mental Hygiene about a patient with lead poisoning who reported taking Vita Breath and two
Belatacept is an investigational agent under development by Bristol-Myers Squibb for the prophylaxis of organ rejection in adult patients receiving kidney transplants. The complete response letter requests the
Abbott Prism Chagas [T cruzi (E coli, Recombinant) Antigen] detects antibodies to T cruzi. The test is manufactured by Abbott Laboratories, based in Abbott Park, Ill. It is
McNeil Consumer Healthcare is initiating this voluntary recall because some of these products may not meet required quality standards. This recall is not being undertaken on the basis
As per the terms of the agreement, Glenmark is expected to receive an upfront payment as well as development, regulatory and commercial milestone payments from Sanofi-aventis. All such
Daiichi Sankyo has presented the study at the American Society of Hypertension (ASH) annual meeting in New York, also found that at week 12, a greater percentage of
Watson’s ANDA is for a generic equivalent of Abbott’s Trilipix product. The suits were filed on April 27, 2010 and April 29, 2010 in the US District Court